Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Knoll pricing Meridia at $2.90-$3.75 per day: high price may restrict anti-obesity use.

Executive Summary

KNOLL MERIDIA LAUNCH PRICE OF $2.90 PER DAY AWP SUGGESTS CONSERVATIVE APPROACH to marketing the once-daily obesity therapy. The price of Meridia (sibutramine) on a daily basis is more than 70% higher than the launch price for Wyeth-Ayerst/Interneuron's now-withdrawn Redux (dexfenfluramine), which cost $1.70 per day AWP. Knoll faces the same relatively unusual marketing challenge Wyeth faced with Redux: a desire to limit the roll-out of its drug to avoid an early spike in sales followed by a drop-off. The high-profile cardiovascular side effects associated with Redux and its predecessor product Pondimin (fenfluramine) has made the obesity market even more sensitive.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031679

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel